BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS Jr; RESCUE and ACTG A5348 study investigators. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. Liver Int 2018;38:1010-21. [PMID: 29091342 DOI: 10.1111/liv.13616] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Scott LJ. Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. Drugs 2018;78:245-56. [DOI: 10.1007/s40265-018-0864-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zarębska-Michaluk D, Buczyńska I, Simon K, Tudrujek-Zdunek M, Janczewska E, Dybowska D, Sitko M, Dobracka B, Jaroszewicz J, Pabjan P, Klapaczyński J, Laurans Ł, Mazur W, Socha Ł, Tronina O, Parczewski M, Flisiak R. Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy. Can J Gastroenterol Hepatol 2019;2019:4029541. [PMID: 30941326 DOI: 10.1155/2019/4029541] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
3 Zaman B, Hassan W. Development of Stability Indicating HPLC-UV Method for Determination of Process Impurities and Degradation Products in Sofosbuvir and Velpatasvir Tablets. Pharm Chem J 2021;54:1295-305. [DOI: 10.1007/s11094-021-02359-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
5 Cosgrove ME, Saadon J, Chesler DA. Colloid cyst curtailed: A case report of spontaneous colloid cyst regression. Surg Neurol Int 2020;11:465. [PMID: 33500803 DOI: 10.25259/SNI_536_2020] [Reference Citation Analysis]
6 Colombo MG, Musabaev EI, Ismailov UY, Zaytsev IA, Nersesov AV, Anastasiy IA, Karpov IA, Golubovska OA, Kaliaskarova KS, AC R, Hadigal S. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions. World J Gastroenterol 2019; 25(29): 3897-3919 [PMID: 31413526 DOI: 10.3748/wjg.v25.i29.3897] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Elshafie S, Trivedi-Kapoor R, Ebell M. Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. J Clin Pharm Ther 2022. [PMID: 35678040 DOI: 10.1111/jcpt.13698] [Reference Citation Analysis]
8 Kozbial K, Al‐zoairy R, Gschwantler M, Stauber R, Hametner S, Laferl H, Strasser M, Hayat‐khayyati A, Datz C, Kramer L, Schaefer B, Maieron A, Graziadei I, Stättermayer AF, Beinhardt S, Munda P, Zoller H, Holzmann H, Aberle SW, Trauner M, Hofer H, Ferenci P. Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy. GastroHep 2019;1:76-83. [DOI: 10.1002/ygh2.329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
9 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]